Plus stock drama, cancer vaccine success, and more news from the AACR conference in Florida this weekApril 21, 2023Check out STAT+Sponsored By Adobe Study: Black women should start breast cancer screening at age 42 At higher risk of dying from breast cancer, Black women should begin screening at age 42, a new study recommends. By Ambar Castillo STAT+ | Novel strategy of attacking sugars on cancer cells to free immune system shows promise in early tests A drug based on work that won a Nobel Prize passes a safety trial. Its aim is to boost the immune system to fight a variety of cancers. By Angus Chen STAT+ | Leaked study results show a CAR-T from J&J providing big benefit for patients with multiple myeloma Carvykti, made with Legend Biotech, reduced the risk of relapse by 74% compared to standard treatment in patients with multiple myeloma. By Adam Feuerstein National Cancer Institute/Massey Cancer Center at Virginia Commonwealth Univ. STAT+ | Relay's breast cancer drug proves tolerable, but market is unimpressed The drug attacked mutations precisely, without causing a common toxic side effect. But it did little to shrink tumors. By Angus Chen Stock drama, cancer vaccine success, and new science — highlights from AACR At the American Association for Cancer Research meeting, stocks crashed, companies debuted compounds, and a mystery got less mysterious. By Angus Chen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments